ClinicalTrials.gg
CompletedNCT03186378Updated Aug 11, 2021Results posted

Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

A Phase 2 interventional study of VP-102 with applicator in Molluscum Contagiosum, sponsored by Verrica Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-11.

Sponsored by Verrica Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Molluscum Contagiosum with a site in United States — none open to participants now, none under way, none of them phase 3. Molluscum Contagiosum · United States.

Enrollment
10th of 15
33 · median 100
Started
2017
with 2 others
Phase 2
5 of 15
none open now
Registered
6th of 15
by date
Lead sponsor
3 of 15
Verrica Pharmaceuticals Inc.

Among the 15 studies in Molluscum Contagiosum with a site in United States, this one is the 10th largest by enrollment, is one of 3 that started in 2017, is one of 5 in phase 2, and was the 6th registered.

Molluscum Contagiosum

22 studies on the registry are indexed under Molluscum Contagiosum; none are open to participants now.

Browse Molluscum Contagiosum studies →

Open to participants now

None of the 15 studies in Molluscum Contagiosum with a site in United States is open now. The open studies under Molluscum Contagiosum, anywhere →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Molluscum Contagiosum with a site in United States as a file.
02

Study summary

The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution [0.7% (w/v) cantharidin] (VP-102) when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older. Treatment will continue over the course of 3 additional 21 day intervals allowing for further evaluation of safety, efficacy and impact on quality of life.

Read the detailed description

This is a Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) cantharidin] in subjects 2 years and older with Molluscum Contagiosum. Up to 40 subjects will be enrolled in the study with the goal of 16 meeting criteria for, and completing all scheduled blood draws outlined in the exposure portion of the trial. Subjects that do not have enough molluscum lesions to participate in the exposure study but do meet all other criteria to participate in the study will be enrolled in the standard treatment group. No more than 16 subjects will complete exposure group activities; up to 16 subjects will be enrolled in the standard treatment group. The additional 8 subjects may be used for replacement patients. At least 3 patients in the exposure group will be from 2-5 years of age. All subjects will receive VP-102 containing 0.7% cantharidin to molluscum lesions every 21 days for a maximum of 4 sessions or until complete clearance.

In the exposure group, blood samples for systemic exposure evaluation will be collected on Day 1, prior to the drug application, and 2 (± 30 minutes), 6 (± 1 hour) and 24 (±3 hours) hours post-application. A dermatological examination will be performed by a qualified investigator quantifying molluscum lesion counts at every study visit.

03

Conditions studied

  • Molluscum Contagiosum

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be healthy subjects ages 2 years and older.
  2. Patients with 1-20 lesions may be enrolled and treated in the standard treatment group but are not eligible for the exposure study.
  3. Patients with 21 or more lesions may only be enrolled in the exposure group. Subjects participating in the Exposure group must have at least 21 lesions treated at Day 1 to qualify.
  4. Be otherwise medically healthy with no medical history as determined by the investigator. Patients exhibiting active Atopic Dermatitis may be enrolled.
  5. Refrain from application of all topical agents including alcohol-based sanitary products and sunscreens for a minimum of 4 hours before Study drug application. Topical agents including alcohol-based sanitary products and sunscreens may be used after application of the study drug so long as they are not applied to or near treated skin.
  6. Refrain from swimming, bathing or prolonged immersion in water until the Study drug is removed.
  7. Have the ability or have a guardian able to follow study instructions and be likely to complete all study requirements.
  8. Provide assent in a manner approved by the institutional review board (IRB) and have a parent/guardian provide written as evidenced by signature on IRB approved assent/consent forms.
  9. Provide written authorization for use and disclosure of protected health information.
  10. Agree to allow photographs of all selected lesions to be taken and/or send photos via text or email to the study team for assessment at 24 hours post treatment. Photos may be used as part of the study data and/or marketing package. (Photographs will be de-identified to those outside the research team. Effort will be made to ensure that no photos with identifiable features are obtained).

Exclusion criteria

Exclusion Criteria:

  1. Are unable to cooperate with the requirements or visits of the study, as determined by the investigator.
  2. Have molluscum venereum (sexually transmitted molluscum).
  3. Have active molluscum eczema.
  4. Are systemically or are receiving treatments such as chemotherapy or other non-topical immunosuppressive agents.
  5. Have had any previous treatment of molluscum in the past 14 days including the use of cantharidin, antivirals, retinoids, curettage or freezing of lesions. Additional treatments for molluscum should not be implemented during the course of the study.
  6. Have history of illness or any dermatologic disorder, which, in the opinion of the investigator will interfere with accurate counting of lesions or increase the risk of adverse events.
  7. History or presence of medical, psychiatric, or emotional condition or abnormality that in the opinion of the investigator would compromise the safety of the subject or the quality of the data.
  8. Have a history or presence of or an idiosyncratic reaction to the Study drug or related compounds, or drug product .
  9. Have a condition or situation that may interfere significantly with the subject's participation in the study (e.g., patients who required hospitalization in the 2 months prior to screening for an acute or chronic condition including alcohol or drug abuse), at the discretion of the investigator.
  10. Have received another product within 14 days prior to the first application of the Study drug.
  11. Have been treated within 14 days with a product that contains the active ingredient in VP-102 (topical or homeopathic preparations) for any reason prior to screening.
  12. Are sexually active or may become sexually active and are unwilling to practice responsible methods. Females that have reached menarche, must have a negative urine pregnancy test at screening and each visit prior to treatment with study medication.
  13. Are pregnant or breastfeeding.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Exposure Group

    This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.

    Combination Product: VP-102 with applicator

  • Experimental
    Standard Group

    This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.

    Combination Product: VP-102 with applicator

Interventions

  • Combination productVP-102 with applicator

    Subjects will receive treatment to their molluscum contagiosum with VP-102.

06

What researchers measure

Primary outcomes

  1. The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102.

    The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older.

    Time frame: 24 hours

Secondary outcomes

  1. Measurement of Efficacy - Complete Clearance

    Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS).

    Time frame: Baseline through EOS Day 84

Other outcomes

  1. Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit.

    Summaries of \>=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit.

    Time frame: Baseline to EOS Day 84

  2. Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit.

    Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit.

    Time frame: Baseline to EOS Day 84

  3. Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit.

    Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit

    Time frame: Baseline to EOS Day 84

  4. Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment

    Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response: * 3: Very much (or Prevented School, Question 7 only) * 2: Quite a lot * 1: Only a little * 0: Not at all

    Time frame: Baseline to EOS Day 84

  5. Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject.

    Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject.

    Time frame: Baseline to EOS Day 84

07

Results

Posted Aug 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneExposure GroupStandard Group
Started1716
Completed1616
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryThe Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102.

The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older.

Time frame:
24 hours
Reported as:
Count of participants · Participants
The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102.
ParticipantsExposure Group
Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment — Yes0
Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment — No16
Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment — Yes1
Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment — No15
Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment — Yes0
Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment — No16
Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment — Yes0
Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment — No16
SecondaryMeasurement of Efficacy - Complete Clearance

Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS).

Time frame:
Baseline through EOS Day 84
Reported as:
Count of participants · Participants
Measurement of Efficacy - Complete Clearance
ParticipantsExposure GroupStandard Group
Complete Clearance Day 2103
Complete Clearance Day 4227
Complete Clearance Day 6349
Complete Clearance EOS Day 84610
Other pre-specifiedProportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit.

Summaries of \>=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit.

Time frame:
Baseline to EOS Day 84
Reported as:
Count of participants · Participants
Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit.
ParticipantsExposure GroupStandard Group
>=90% Clearance Day 2103
>=90% Clearance Day 4257
>=90% Clearance Day 63810
>=90% Clearance Day 841213
Other pre-specifiedPercent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit.

Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit.

Time frame:
Baseline to EOS Day 84
Reported as:
Mean · percentage change from Baseline
Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit.
percentage change from BaselineExposure GroupStandard Group
Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit.-87.8 ± 21.25-93.0 ± 12.93
Other pre-specifiedChange From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit.

Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit

Time frame:
Baseline to EOS Day 84
Reported as:
Mean · change in wart count
Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit.
change in wart countExposure GroupStandard Group
Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit.-39.3 ± 21.98-10.7 ± 6.16
Other pre-specifiedChange From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment

Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response: * 3: Very much (or Prevented School, Question 7 only) * 2: Quite a lot * 1: Only a little * 0: Not at all

Time frame:
Baseline to EOS Day 84
Reported as:
Mean · units on a scale change from Baseline
Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment
units on a scale change from BaselineExposure GroupStandard Group
Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment2.71 ± 2.8012.44 ± 4.115
Other pre-specifiedSpread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject.

Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject.

Time frame:
Baseline to EOS Day 84
Reported as:
Count of participants · Participants
Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject.
ParticipantsExposure GroupStandard Group
Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject.00

Adverse events

Collected over Baseline to EOS Day 84. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exposure Group0/17 (0%)0/17 (0%)16/17 (94.1%)
Standard Group0/16 (0%)0/16 (0%)13/16 (81.3%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventExposure GroupStandard Group
PainGeneral disorders11/178/16
CoughRespiratory, thoracic and mediastinal disorders3/173/16
HeadacheNervous system disorders2/173/16
VomitingGastrointestinal disorders1/173/16
ScarSkin and subcutaneous tissue disorders3/171/16
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/172/16
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/171/16
EpistaxisRespiratory, thoracic and mediastinal disorders0/171/16
Paranasal sinus hypersecretionRespiratory, thoracic and mediastinal disorders0/171/16
Respiratory tract congestionRespiratory, thoracic and mediastinal disorders0/171/16

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(years)Exposure GroupStandard GroupTotal
Mean6.6 ± 3.456.8 ± 3.156.7 ± 3.26
Sex: Female, Male
Sex: Female, Male(Participants)Exposure GroupStandard GroupTotal
Female7815
Male10818
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Exposure GroupStandard GroupTotal
Hispanic or Latino022
Not Hispanic or Latino171431
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Exposure GroupStandard GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American123
White161430
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Exposure GroupStandard GroupTotal
United States171633
Baseline Number of Molluscum Lesions
Baseline Number of Molluscum Lesions(molluscum lesions)Exposure GroupStandard GroupTotal
Mean47.4 ± 25.6911.6 ± 6.3330.0 ± 26.07
08

Study locations

1 site
  • Midwest Children's Health
    Lincoln, Nebraska 68522, United States
09

References and documents

Publications

  • Niazi S, Brabec B, Anschutz L, Willson C, Davidson M, Burnett P. A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum. J Drugs Dermatol. 2021 Jan 1;20(1):70-75. doi: 10.36849/JDD.5626. PubMed 33400412 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jun 2018, 12 months.

Results were first posted in Aug 2021, 3 years 1 month after primary completion. A results delay was requested in Jul 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2017
First posted
Jun 14, 2017
StartActual
Jun 8, 2017
Primary completionActual
Jun 25, 2018
CompletionActual
Jun 25, 2018
Results delay requested
Jul 4, 2019
Results first posted
Aug 9, 2021
Last update
Aug 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03186378
Lead sponsor
Verrica Pharmaceuticals Inc.
Collaborators
Paidion Research, Inc., Database Integrations, Inc., Cato Research, Instat Services
Responsible party
Sponsor
First posted
Jun 14, 2017
Start date
Jun 8, 2017
Primary completion
Jun 25, 2018
Completion
Jun 25, 2018
Results posted
Aug 9, 2021
Last update
Aug 11, 2021

Study contacts

Gary Goldenberg, MD
study director · Verrica Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion